- Home
- ERAS vs ORIC Comparison
ERAS vs ORIC Comparison
Compare ERAS & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- ORIC
- Stock Information
- Founded
- ERAS 2018
- ORIC 2014
- Country
- ERAS United States
- ORIC United States
- Employees
- ERAS N/A
- ORIC N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- ERAS Health Care
- ORIC Health Care
- Exchange
- ERAS Nasdaq
- ORIC Nasdaq
- Market Cap
- ERAS 396.6M
- ORIC 362.9M
- IPO Year
- ERAS 2021
- ORIC 2020
- Fundamental
- Price
- ERAS $1.39
- ORIC $5.08
- Analyst Decision
- ERAS Strong Buy
- ORIC Strong Buy
- Analyst Count
- ERAS 6
- ORIC 8
- Target Price
- ERAS $4.83
- ORIC $18.83
- AVG Volume (30 Days)
- ERAS 1.4M
- ORIC 630.2K
- Earning Date
- ERAS 05-20-2025
- ORIC 05-05-2025
- Dividend Yield
- ERAS N/A
- ORIC N/A
- EPS Growth
- ERAS N/A
- ORIC N/A
- EPS
- ERAS N/A
- ORIC N/A
- Revenue
- ERAS N/A
- ORIC N/A
- Revenue This Year
- ERAS N/A
- ORIC N/A
- Revenue Next Year
- ERAS N/A
- ORIC N/A
- P/E Ratio
- ERAS N/A
- ORIC N/A
- Revenue Growth
- ERAS N/A
- ORIC N/A
- 52 Week Low
- ERAS $1.01
- ORIC $3.90
- 52 Week High
- ERAS $3.45
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- ERAS 51.46
- ORIC 44.71
- Support Level
- ERAS $1.37
- ORIC $4.52
- Resistance Level
- ERAS $1.61
- ORIC $5.83
- Average True Range (ATR)
- ERAS 0.14
- ORIC 0.52
- MACD
- ERAS 0.00
- ORIC 0.07
- Stochastic Oscillator
- ERAS 45.68
- ORIC 40.58
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.